Elimination of duplicated functions and enhancement of the management structure through group organizational restructuring
First written in FY2017. 14 of 19 entries say "Advanced", first in FY2018-Q2. Latest entry: FY2026.
26 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「On 8 April 2025, the consolidated subsidiary ㈱なの花東日本 acquired all shares of ㈲メディコプランニング and, on 1 October 2025, carried out an absorption-type merger with ㈱なの花東日本 as the surviving company. On 27 August 2025, the consolidated subsidiary ㈱なの花北海道 acquired all shares of ㈱クライマー. On 21 November 2025, the consolidated subsidiary ㈱なの花中部 acquired all shares of ㈱アカマル and, on 1 March 2026, carried out an absorption-type merger with ㈱なの花中部 as the surviving company.」
Pharmacy companies were acquired in multiple regions, followed by absorption-type mergers of the acquired companies, advancing organizational integration and the restructuring of the store network. - FY2026-H1AdvancedAnnual report
「The consolidated subsidiaries 株式会社なの花九州, 株式会社永冨調剤薬局, 株式会社鶴丸調剤薬局 and 株式会社白十字総合薬局 carried out a merger by absorption on 1 April 2025, with 株式会社なの花九州 as the surviving company.」
An organizational restructuring was carried out to integrate 4 companies in the Kyushu region into なの花九州, and the organizational restructuring plan progressed to a new implementation stage. - FY2025AdvancedAnnual report
「The consolidated subsidiaries ㈱なの花東北, ㈱コスモス薬局 and ㈱山形アポテック carried out a merger by absorption on 1 October 2024, with ㈱なの花東北 as the surviving company.」
As part of the group organizational restructuring, an absorption-type merger was carried out with なの花東北 as the surviving company. It was also disclosed that 4 consolidated subsidiaries in the Kyushu region are scheduled to be integrated and their corporate name changed to 株式会社なの花九州 on 1 April 2025. - FY2024-Q1ReframedAnnual report
「From the first quarter of the current consolidated fiscal year, expenses for the Business Development Department previously recorded in the rental and equipment-related business have been transferred to the regional pharmacy network business because the department is now dedicated to developing the Company's regional pharmacies (the amount transferred during the cumulative first-quarter period was ¥46 million).」
The management classification was changed so that the Business Development Department would focus on developing regional pharmacies and its expenses would be transferred from the rental and equipment-related business to the regional pharmacy network business. - FY2022AdvancedAnnual report
「On 1 July 2021, the Company and its consolidated subsidiary ㈱ひまわり看護ステーション carried out an absorption-type merger, with the Company as the surviving company.」
An absorption-type merger of ひまわり看護ステーション was carried out, advancing the integration of the group organization. The business structure integrating the regional pharmacy network, pharmaceutical manufacturing and marketing, and digital transformation also continues. - FY2022-Q3AdvancedAnnual report
「The consolidated subsidiary 株式会社なの花北海道 acquired all shares of 有限会社クリニクス effective 1 April 2021 and carried out a merger by absorption effective 1 October 2021, with 株式会社なの花北海道 as the surviving company.」
In addition to the acquisition and absorption-type merger of クリニクス, absorption-type mergers of メトロファーマシー and ひまわり看護ステーション were also carried out, advancing the organizational restructuring. - FY2022-Q2AdvancedAnnual report
「The Company and its consolidated subsidiary 株式会社ひまわり看護ステーション carried out a merger by absorption effective 1 July 2021, with the Company as the surviving company.」
As part of the organizational restructuring, ひまわり看護ステーション was absorbed by the Company. - FY2022-Q1AdvancedAnnual report
「The consolidated subsidiaries 株式会社なの花東日本 and 株式会社メトロファーマシー carried out a merger by absorption effective 1 June 2021, with 株式会社なの花東日本 as the surviving company.」
As part of the group organizational restructuring, an absorption-type merger between なの花東日本 and メトロファーマシー was carried out. - FY2021RestatedAnnual report
「With respect to this business, we provide management support to pharmacies and other businesses through the pharmaceutical network, operate pharmacies, and manufacture and market pharmaceuticals, with the aim of promoting the provision of value across the entire pharmaceutical supply chain.」
The business structure integrating the pharmaceutical network, pharmacy and pharmaceutical manufacturing and marketing businesses and providing value across the entire pharmaceutical supply chain continues. - FY2021-Q1RestatedAnnual report
「With respect to this business, we provide management support to pharmacies and other businesses through the pharmaceutical network, operate pharmacies, and manufacture and market pharmaceuticals, with the aim of promoting the provision of value across the entire pharmaceutical supply chain.」
The business structure integrating the network, pharmacy and pharmaceutical manufacturing and marketing businesses and providing value across the entire pharmaceutical supply chain continues. - FY2020-Q2AdvancedAnnual report
「From the first quarter of the fiscal year, the reporting segments were changed from 5 segments, namely the pharmaceutical and other network business, pharmacy business, rental and equipment-related business, school meal business and Other business, to 4 segments, namely the regional pharmacy network business, rental and equipment-related business, school meal business and Other business. Against the backdrop of the sharp increase in member stores in the pharmaceutical network following the start of application of the distribution improvement guidelines in April 2018, as well as the expansion of the business domain following the launch of the pharmaceutical manufacturing and marketing business, we changed our structure from April 2019 to manage the pharmaceutical and other network business, pharmacy business and pharmaceutical manufacturing and marketing business on an integrated basis in order to promote the provision of value across the entire supply chain. At the same time, these 3 businesses were integrated into the regional pharmacy network business.」
The management structure integrating the pharmaceutical network, pharmacy and pharmaceutical manufacturing and marketing businesses into the regional pharmacy network business was also reflected in the reporting segments from April 2019. - FY2020-Q1AdvancedAnnual report
「The Company and its consolidated subsidiary 株式会社Ａ－システム carried out a merger by absorption effective 1 April 2019, with the Company as the surviving company.」
As part of the group organizational restructuring, A-System was absorbed by the Company. - FY2019ReframedAnnual report
「As the business domain expanded across the entire supply chain through an increase in member stores in the pharmaceutical network and the launch of the pharmaceutical manufacturing and marketing business, we changed our management structure to promote the provision of value across the entire supply chain while taking into account the potential for conflicts of interest between the pharmaceutical network business, pharmacy business and pharmaceutical manufacturing and marketing business.」
The organizational and management focus was reorganized from restructuring centered on integrating subsidiaries to a management structure centered on providing value across the entire supply chain and taking account of conflicts of interest between businesses. - FY2019-Q2AdvancedAnnual report
「The consolidated subsidiaries 株式会社アポテック, 株式会社ラパナ, 株式会社メディセーブ and 株式会社コスディック carried out a merger by absorption effective 1 July 2018, with 株式会社アポテック as the surviving company.」
As part of the organizational restructuring plan, an absorption-type merger between subsidiaries was carried out with アポテック as the surviving company, advancing group integration. - FY2019-Q1AdvancedAnnual report
「The consolidated subsidiaries 株式会社共栄ファーマシー, 有限会社いかるが薬局 and ヘルシートラスト株式会社 carried out a merger by absorption effective 1 April 2018, with 株式会社共栄ファーマシー as the surviving company. The consolidated subsidiaries 株式会社トータル・メディカルサービス and 九州医療食株式会社 carried out a merger by absorption effective 1 April 2018, with 株式会社トータル・メディカルサービス as the surviving company.」
As part of the group organizational restructuring plan, an absorption-type merger between subsidiaries was carried out on 1 April 2018. - FY2018AdvancedAnnual report
「With 1 October 2017 as the effective date, we absorbed the wholly owned subsidiaries 株式会社システム・フォー, 株式会社ファーマホールディング and 株式会社日本レーベン.」
The plan to eliminate duplicated functions between organizations, streamline the management structure and accelerate decision-making progressed to the implementation stage, with 3 companies being absorbed by the Company. - FY2018-Q3AdvancedAnnual report
「On 1 October 2017, we carried out an absorption-type merger with the consolidated subsidiaries 株式会社システム・フォー, 株式会社ファーマホールディング and 株式会社日本レーベン, with the Company as the surviving company. アイ・エス・メディカル㈱, formerly a consolidated subsidiary, was excluded from the scope of consolidation because it merged with the consolidated subsidiary ㈱なの花東日本 (which had changed its corporate name from ㈱サンメディック).」
An absorption-type merger of 3 companies was carried out with the Company as the surviving company, followed by a merger between アイ・エス・メディカル and 株式会社なの花東日本. Group organizational restructuring progressed to the implementation stage. - FY2018-Q2AdvancedAnnual report
「The consolidated subsidiary 株式会社コムファ changed its corporate name to 株式会社なの花北海道 on 1 June 2017. The consolidated subsidiaries 株式会社なの花北海道, 株式会社アポス and 株式会社エスケイアイファーマシー carried out an absorption-type merger on 1 July 2017, with 株式会社なの花北海道 as the surviving company. 株式会社ファーマホールディング, 株式会社システム・フォー and 株式会社日本レーベン ceased to exist as a result of an absorption-type merger on 1 October 2017, with the Company as the surviving company.」
In addition to absorption-type mergers between subsidiaries, an organizational restructuring was carried out on 1 October 2017 in which 3 companies were absorbed by the Company. - FY2017First statedAnnual report
「For the fiscal year ending March 2018, we plan to restructure the organization of our group. By reorganizing businesses beyond the framework of each consolidated subsidiary and bringing together our human resources, we will seek to reduce costs by eliminating duplicated functions between organizations, establish a management structure for further growth, strengthen group governance and accelerate decision-making. We will build an optimal group organizational structure and further strengthen our business foundation.」
For the fiscal year ending March 2018, the Company first explicitly disclosed plans to reorganize businesses beyond the framework of its subsidiaries, bring together human resources, eliminate duplicated functions, strengthen group governance and accelerate decision-making.